IP Library Granted Patent US 9,452,964
Granted Patent B2
US 9,452,964 · App. 14/674,025 · Granted Sep 27, 2016

Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses

Inventors: Jean-Louis H. Dasseux (Toulouse, FR); Carmen D. Oniciu (Toulouse, FR)
Assignee: Esperion Therapeutics, Inc.
C07C31/27C07C31/20C07C31/22C07C31/24C07C33/26C07C47/19C07C47/34C07C59/01C07C59/105C07C59/11C07C59/245C07C59/285C07C59/29C07C59/46C07C59/48C07C59/54C07C61/12C07C62/02C07C62/06C07C65/17C07C69/003C07C69/017C07C69/675C07C69/757C07C255/00C07C309/08C07C309/24C07C309/25C07D213/80C07D257/04C07D261/08C07D261/12C07D305/12C07D307/33C07D309/10C07D309/12C07D309/30C07D405/12C07D495/04C07F9/093C07F9/094C07F9/11C07F9/117C07F9/12C07F9/242C07F9/2408C07F9/2416C07F9/2425C07F9/4423C07C2101/02C07C2101/04C07C2101/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,452,964
App. No.
14/674,025
Granted
Sep 27, 2016
Kind
B2
Abstract

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Claims (31)

1. A compound of formula I:

or a pharmaceutically acceptable salt thereof, wherein:

(a) each occurrence of m is independently an integer ranging from 0 to 5;

(b) each occurrence of n is independently an integer ranging from 3 to 7;

(c) X is (CH 2 ) z or Ph, wherein z is an integer from 0 to 4;

(d) each occurrence of R 1 and R 2 is independently (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl, benzyl, or R 1 and R 2 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloakyl group;

(e) each occurrence of R 11 and R 12 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloakyl group;

(f) each occurrence of Y 1 and Y 2 is independently (C 1 -C 6 )aikyl, OH, COOH, COOR S , SO 3 H,

wherein:

(i) R 3 is (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, phenyl, or benzyl and is unsubstituted or substituted with one or more halo, OH, (C 1 -C 6 )alkoxy, or phenyl groups,

(ii) each occurrence of R 4 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C 2 -C 6 )alkynyl and is unsubstituted or substituted with one or two halo, OH, C 1 -C 6 alkoxy, or phenyl groups; and

(iii) each occurrence of R 5 is independently H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, or (C 2 -C 6 )alkynyl.

2. The compound of claim 1 , wherein each occurrence of Y 1 and Y 2 is independently OH, COOR 3 , or COOH.

3. The compound of claim 1 , wherein m is 0.

4. The compound of claim 1 , wherein m is 1.

5. The compound of claim 1 , wherein n is 4.

6. The compound of claim 1 , wherein n is 5.

7. The compound of claim 1 , wherein X is (CH 2 ) z and z is 0.

8. The compound of claim 1 , wherein each occurrence of R 1 and R 2 and the carbon to which they are both attached are taken together to form a (C 3 -C 7 )cycloakyl group.

9. The compound of claim 1 , wherein Y 1 and Y 2 are each independently (C 1 -C 6 )alkyl.

10. The compound of claim 1 , wherein Y 1 and Y 2 are each methyl.

11. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable vehicle.

12. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable vehicle.

13. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable vehicle.

14. A pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable vehicle.

15. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable vehicle.

16. A pharmaceutical composition comprising a compound of claim 6 and a pharmaceutically acceptable vehicle.

17. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable vehicle.

18. A pharmaceutical composition comprising a compound of claim 8 and a pharmaceutically acceptable vehicle.

19. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable vehicle.

20. A pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable vehicle.

Assignments (2)
MERGER Recorded Aug 7, 2017
From: ESPERION THERAPEUTICS, INC.
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 043218/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 16, 2016
From: DASSEUX, JEAN-LOUIS HENRI; ONICIU, CARMEN DANIELA
To: ESPERION THERAPEUTICS, INC.
Reel/Frame 039457/0084 →
Continuity (9)
Continuation 14138919 · Dec 23, 2013
Continuation 13650852 · Oct 12, 2012
Continuation 13414855 · Mar 8, 2012
Continuation 13270297 · Oct 11, 2011
Continuation 12135504 · Jun 9, 2008
Continuation 11426380 · Jun 26, 2006
Division 10743287 · Dec 23, 2003
Provisional Application 60441795 · Jan 23, 2003
Related Publication 20150344389A1 · Dec 3, 2015